Lexicon Pharmaceuticals (NASDAQ:LXRX) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report sent to investors on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded shares of Lexicon Pharmaceuticals to a sell rating in a research note on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and a consensus price target of $7.50.

Lexicon Pharmaceuticals Trading Down 1.9 %

NASDAQ:LXRX opened at $1.57 on Friday. The company has a market cap of $386.59 million, a P/E ratio of -1.89 and a beta of 1.33. Lexicon Pharmaceuticals has a twelve month low of $0.92 and a twelve month high of $3.73. The business has a 50 day moving average price of $1.75 and a two-hundred day moving average price of $1.83. The company has a quick ratio of 11.49, a current ratio of 11.51 and a debt-to-equity ratio of 0.41.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01. The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. During the same quarter in the previous year, the firm posted ($0.22) earnings per share. As a group, analysts expect that Lexicon Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Principal Financial Group Inc. increased its holdings in Lexicon Pharmaceuticals by 116.1% during the second quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Lexicon Pharmaceuticals by 44.5% during the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 13,972 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Lexicon Pharmaceuticals by 40.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,957 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 14,411 shares during the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $25,000. Finally, Pinnacle Associates Ltd. lifted its stake in Lexicon Pharmaceuticals by 1.0% in the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company’s stock valued at $4,195,000 after purchasing an additional 17,009 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.